Rituximab plus lenalidomide provides comparable progression-free survival to rituximab-based immunochemotherapy in advanced follicular lymphomaTrial shows lenalidomide and rituximab for advanced follicular lymphoma

This Phase 3 randomized controlled trial evaluated the efficacy and safety of rituximab plus lenalidomide (R2) compared to standard rituximab-based immunochemotherapy (R-Chemo) in a multinational setting. The study enrolled 1030 patients with previously untreated advanced follicular lymphoma, providing a robust sample size for assessing long-term outcomes in this patient population.

The primary objective was to assess progression-free survival (PFS). Patients were randomized to receive either the R2 regimen or the R-Chemo regimen. The study included a substantial follow-up period of 120.0 months, allowing for a comprehensive analysis of long-term durability and safety profiles.

Regarding the primary outcome, the median progression-free survival (PFS) was 110.6 months in the R2 group compared to 102.8 months in the R-Chemo group. Furthermore, the 10-year PFS rates were nearly identical between the two groups, reported as 46.4% for R2 and 46.6% for R-Chemo. These results indicate that the addition of lenalidomide to rituximab provides a comparable survival profile to traditional immunochemotherapy over a decade.

Secondary outcomes included overall survival (OS), time-to-next lymphoma treatment (TTNLT), second primary malignancies (SPMs), and transformations. The 10-year OS rates were 82.4% for the R2 group and 81.1% for the R-Chemo group, again showing comparable results. However, the 10-year TTNLT rates were 62.2% for R2 versus 66.3% for R-Chemo. A significant finding was noted regarding progression of disease within 24 months (POD24); patients with POD24 had a significantly poorer prognosis compared to those without POD24, with a hazard ratio of 6.215 and a p-value of <.0001.

Safety and tolerability data were not specifically detailed in the provided results regarding adverse event rates or discontinuation rates. However, the trial's design as a Phase 3 study with a 120.0-month follow-up provides high certainty regarding the long-term durability of the R2 regimen.

These findings are significant because they establish R2 as a chemotherapy-free alternative to standard immunochemotherapy for patients with advanced follicular lymphoma. While R-Chemo has been a cornerstone of treatment, the comparable 10-year outcomes suggest that R2 may offer a less intensive treatment path without sacrificing efficacy. Methodological limitations were not specifically detailed; however, the large sample size and long follow-up period strengthen the reliability of the findings. Clinical implications for practice are significant: clinicians can consider R2 as an effective alternative to chemotherapy-containing regimens for patients who may prefer or require a less intensive treatment schedule.

Questions remain regarding the specific management of side effects associated with lenalidomide and how these might influence patient adherence over long periods compared to standard chemotherapies. Additionally, further data on secondary primary malignancies (SPMs) and transformations would provide more granular detail on the long-term safety profile of R2.